The journey between identifying a potential therapeutic compound and Food and Drug Administration approval of a new drug can take well over a decade and cost upwards of a billion dollars. A research team at the CUNY Graduate Center has created an artificial intelligence model that could significantly improve the accuracy and reduce the time and cost of the drug development process.

Wear and tear on joints can lead to inflammation, breakdown of cartilage and development of osteoarthritis. Scientists at UF Scripps Biomedical Research have found a possible new target to fight this painful cascade.

In a study published Thursday in the journal PLOS One,biochemist Patrick Griffin, Ph.D., and colleague Mi Ra Chang, Ph.D., describe a specific protein that manages activities within chondrocytes, a critical cell type that maintains healthy cartilage in joints.

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF). Saracatinib worked as well or better than two approved drugs at reducing tissue scarring in preclinical models of IPF according to the study published in the American Journal of Respiratory and Critical Care Medicine.

In the article published in the prestigious scientific journal Science, a group of international researchers, including Gorka Orive, Doctor of Pharmacy and researcher in the UPV/EHU's NanoBioCel group, and Unax Lertxundi of the Bioaraba Institute for Health Research, have issued a warning about the increase in pharmaceutical contamination.

Michigan State University (MSU) researchers are using big data and AI to identify current drugs that could be applied to treat new COVID-19 variants.

Finding new ways to treat the novel coronavirus and its ever-changing variants has been a challenge for researchers, especially when the traditional drug development and discovery process can take years.

Cancer is in Switzerland the second leading cause of death. Among the different types of cancers, non-small cell lung cancer (NSCLC) kills the most patients and remains largely incurable. Unfortunately, even newly approved therapies can extend the life of patients only by a few months and only few survive the metastatic stadium long-term.

An obscure family of viruses, already endemic in wild African primates and known to cause fatal Ebola-like symptoms in some monkeys, is “poised for spillover” to humans, according to new University of Colorado Boulder research published online Sept. 30 in the journal Cell.